Pediatric Cannabis Hyperemesis Protocol Increases Capsaicin Use and Lowers Haloperidol Dosing

Cannabis hyperemesis syndrome has emerged as a frequent and costly challenge in pediatric emergency departments, particularly in regions where recreational markets have commercialized [1, 2]. Characterized by cyclic episodes of severe vomiting and abdominal pain, the condition often progresses through distinct prodromal and hyperemetic phases that can lead to severe dehydration and electrolyte imbalances in adolescent patients [3, 4]. Traditional antiemetic regimens, such as ondansetron, frequently fail to provide relief, prompting clinicians to explore alternative therapies including dopamine antagonists and topical capsaicin [5, 6]. However, the lack of standardized treatment protocols often leads to exhaustive diagnostic testing and inconsistent prescribing patterns [6, 4]. A new study now evaluates how the formal implementation of a management algorithm influences medication selection and patient throughput in an academic pediatric setting.